TY - JOUR
T1 - Upregulated Seizure-Related 6 Homolog-Like 2 Is a Prognostic Predictor of Hepatocellular Carcinoma
AU - Wang, Linhe
AU - Ling, Xiangchao
AU - Zhu, Caihui
AU - Zhang, Zhiheng
AU - Wang, Ziming
AU - Huang, Shanzhou
AU - Tang, Yunhua
AU - He, Shujiao
AU - Guo, Zhiyong
AU - He, Xiaoshun
N1 - Funding Information:
Seizure-related 6 homolog-like 2 ( SEZ6L2 ), which is localized on the cell surface, has been found to be associated with tumor angiogenesis and lung cancer progression. However, the role of SEZ6L2 in hepatocellular carcinoma (HCC) is still unclear. We obtained data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) to investigate SEZ6L2 expression and regulation in HCC. Then, HCC tissue samples were collected to verify SEZ6L2 by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemical staining (IHC). Patient information was collected for survival and prognosis analysis. qRT-PCR, IHC, and bioinformatics analysis showed that the SEZ6L2 protein was highly expressed in HCC samples. Clinical data showed that high SEZ6L2 protein expression was correlated with tumor-node-metastasis (TNM) stages ( P = 0.046 ), tumor number ( P = 0.016 ), and tumor size ( P = 0.029 ). Meanwhile, SEZ6L2 overexpression was closely associated with poor overall survival and disease-free survival in HCC patients. Moreover, SEZ6L2 is an independent prognostic predictor for the survival of HCC patients. This study suggests a significant correlation between SEZ6L2 and HCC, which means that SEZ6L2 may potentially serve as a useful prognostic biomarker for HCC patients. Guangdong Provincial Key Laboratory Construction Project on Organ Donation and Transplant Immunology 2013A061401007 Guangdong Provincial International Cooperation Base of Science and Technology (Organ Transplantation) 2015B050501002 Special Support Program for Training High-Level Talent in Guangdong Province 2015TQ01R168 Natural Science Foundation of Guangdong Province 2015A030306025
Funding Information:
This study was supported by the Guangdong Provincial Natural Science Funds for Distinguished Young Scholars (2015A030306025), the Special Support Program for Training High-Level Talent in Guangdong Province (2015TQ01R168), the Guangdong Provincial International Cooperation Base of Science and Technology (Organ Transplantation) (2015B050501002), and the Guangdong Provincial Key Laboratory Construction Project on Organ Donation and Transplant Immunology (No. 2013A061401007)
Publisher Copyright:
© 2020 Linhe Wang et al.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Seizure-related 6 homolog-like 2 (SEZ6L2), which is localized on the cell surface, has been found to be associated with tumor angiogenesis and lung cancer progression. However, the role of SEZ6L2 in hepatocellular carcinoma (HCC) is still unclear. We obtained data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) to investigate SEZ6L2 expression and regulation in HCC. Then, HCC tissue samples were collected to verify SEZ6L2 by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemical staining (IHC). Patient information was collected for survival and prognosis analysis. qRT-PCR, IHC, and bioinformatics analysis showed that the SEZ6L2 protein was highly expressed in HCC samples. Clinical data showed that high SEZ6L2 protein expression was correlated with tumor-node-metastasis (TNM) stages (P=0.046), tumor number (P=0.016), and tumor size (P=0.029). Meanwhile, SEZ6L2 overexpression was closely associated with poor overall survival and disease-free survival in HCC patients. Moreover, SEZ6L2 is an independent prognostic predictor for the survival of HCC patients. This study suggests a significant correlation between SEZ6L2 and HCC, which means that SEZ6L2 may potentially serve as a useful prognostic biomarker for HCC patients.
AB - Seizure-related 6 homolog-like 2 (SEZ6L2), which is localized on the cell surface, has been found to be associated with tumor angiogenesis and lung cancer progression. However, the role of SEZ6L2 in hepatocellular carcinoma (HCC) is still unclear. We obtained data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) to investigate SEZ6L2 expression and regulation in HCC. Then, HCC tissue samples were collected to verify SEZ6L2 by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemical staining (IHC). Patient information was collected for survival and prognosis analysis. qRT-PCR, IHC, and bioinformatics analysis showed that the SEZ6L2 protein was highly expressed in HCC samples. Clinical data showed that high SEZ6L2 protein expression was correlated with tumor-node-metastasis (TNM) stages (P=0.046), tumor number (P=0.016), and tumor size (P=0.029). Meanwhile, SEZ6L2 overexpression was closely associated with poor overall survival and disease-free survival in HCC patients. Moreover, SEZ6L2 is an independent prognostic predictor for the survival of HCC patients. This study suggests a significant correlation between SEZ6L2 and HCC, which means that SEZ6L2 may potentially serve as a useful prognostic biomarker for HCC patients.
UR - http://www.scopus.com/inward/record.url?scp=85080965226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080965226&partnerID=8YFLogxK
U2 - 10.1155/2020/7318703
DO - 10.1155/2020/7318703
M3 - Article
C2 - 32148567
AN - SCOPUS:85080965226
VL - 2020
JO - Disease Markers
JF - Disease Markers
SN - 0278-0240
M1 - 7318703
ER -